Jefferies assumed coverage of Celldex with a Buy rating and price target of $68, down from $70. Celldex is developing barzolvolimab in inflammatory diseases as a “pipeline in a product” and reported “very impressive” Phase 1/2 results that support ongoing studies of barzolvolimab in the lead indication of chronic urticaria, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLDX:
- Celldex believes it has sufficient cash, securities to fund through 2025
- Celldex reports Q2 EPS (65c), consensus (67c)
- Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- Celldex completes enrollment in Phase 2 study of barzolvolimab
- Celldex doses first patient in Phase 2 study of barzolvolimab